These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 19965851)
21. Functional imaging of the cerebral olfactory system in patients with Parkinson's disease. Westermann B; Wattendorf E; Schwerdtfeger U; Husner A; Fuhr P; Gratzl O; Hummel T; Bilecen D; Welge-Lüssen A J Neurol Neurosurg Psychiatry; 2008 Jan; 79(1):19-24. PubMed ID: 17519323 [TBL] [Abstract][Full Text] [Related]
22. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Iranzo A; Valldeoriola F; Lomeña F; Molinuevo JL; Serradell M; Salamero M; Cot A; Ros D; Pavía J; Santamaria J; Tolosa E Lancet Neurol; 2011 Sep; 10(9):797-805. PubMed ID: 21802993 [TBL] [Abstract][Full Text] [Related]
23. Serial olfactory testing for the diagnosis of prodromal Parkinson's disease in the PARS study. Vaswani PA; Morley JF; Jennings D; Siderowf A; Marek K; Parkinsonism Relat Disord; 2022 Nov; 104():15-20. PubMed ID: 36194902 [TBL] [Abstract][Full Text] [Related]
24. Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients. Santangelo G; Vitale C; Picillo M; Cuoco S; Moccia M; Pezzella D; Erro R; Longo K; Vicidomini C; Pellecchia MT; Amboni M; Brunetti A; Salvatore M; Barone P; Pappatà S Parkinsonism Relat Disord; 2015 May; 21(5):489-93. PubMed ID: 25753457 [TBL] [Abstract][Full Text] [Related]
26. No link between striatal dopaminergic axons and dopamine transporter imaging in Parkinson's disease. Honkanen EA; Saari L; Orte K; Gardberg M; Noponen T; Joutsa J; Kaasinen V Mov Disord; 2019 Oct; 34(10):1562-1566. PubMed ID: 31234224 [TBL] [Abstract][Full Text] [Related]
27. Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Sommer U; Hummel T; Cormann K; Mueller A; Frasnelli J; Kropp J; Reichmann H Mov Disord; 2004 Oct; 19(10):1196-202. PubMed ID: 15390014 [TBL] [Abstract][Full Text] [Related]
29. Reduced dopamine transporter binding predates impulse control disorders in Parkinson's disease. Vriend C; Nordbeck AH; Booij J; van der Werf YD; Pattij T; Voorn P; Raijmakers P; Foncke EM; van de Giessen E; Berendse HW; van den Heuvel OA Mov Disord; 2014 Jun; 29(7):904-11. PubMed ID: 24832846 [TBL] [Abstract][Full Text] [Related]
30. Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations. Benamer HT; Oertel WH; Patterson J; Hadley DM; Pogarell O; Höffken H; Gerstner A; Grosset DG Mov Disord; 2003 Sep; 18(9):977-84. PubMed ID: 14502664 [TBL] [Abstract][Full Text] [Related]
31. Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study. Tinazzi M; Morgante F; Matinella A; Bovi T; Cannas A; Solla P; Marrosu F; Nicoletti A; Zappia M; Luca A; Di Stefano A; Morgante L; Pacchetti C; Minafra B; Sciarretta M; Dallocchio C; Rossi S; Ulivelli M; Ceravolo R; Frosini D; Cipriani A; Barbui C Schizophr Res; 2014 Feb; 152(2-3):344-9. PubMed ID: 24369987 [TBL] [Abstract][Full Text] [Related]
32. Hyposmia and executive dysfunction as predictors of future Parkinson's disease: a prospective study. Ponsen MM; Stoffers D; Twisk JW; Wolters ECh; Berendse HW Mov Disord; 2009 May; 24(7):1060-5. PubMed ID: 19353591 [TBL] [Abstract][Full Text] [Related]
33. Measuring the rate of progression of Parkinson's disease over a 5-year period with beta-CIT SPECT. Pirker W; Holler I; Gerschlager W; Asenbaum S; Zettinig G; Brücke T Mov Disord; 2003 Nov; 18(11):1266-72. PubMed ID: 14639666 [TBL] [Abstract][Full Text] [Related]
34. Growth hormone response in low-dose apomorphine test correlates with nigrostriatal dopamine transporter binding in patients with Parkinson's disease. Happe S; Tings T; Koch W; Welsch J; Helmschmied K; Baier PC; Meller J; Wuttke W; Paulus W; Tatsch K; Trenkwalder C J Neural Transm (Vienna); 2007; 114(5):589-94. PubMed ID: 17187291 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of RNA Blood Biomarkers in Individuals at Risk of Parkinson's Disease. Santiago JA; Potashkin JA J Parkinsons Dis; 2017; 7(4):653-660. PubMed ID: 28922168 [TBL] [Abstract][Full Text] [Related]
36. Olfactory function in Parkinson's Disease - effects of training. Knudsen K; Flensborg Damholdt M; Mouridsen K; Borghammer P Acta Neurol Scand; 2015 Dec; 132(6):395-400. PubMed ID: 25846906 [TBL] [Abstract][Full Text] [Related]
37. Association of daytime sleepiness with nigrostriatal dopaminergic degeneration in early Parkinson's disease. Happe S; Baier PC; Helmschmied K; Meller J; Tatsch K; Paulus W J Neurol; 2007 Aug; 254(8):1037-43. PubMed ID: 17351722 [TBL] [Abstract][Full Text] [Related]
38. MRI diffusion in Parkinson's disease: using the technique's inherent directional information to study the olfactory bulb and substantia nigra. Skorpil M; Söderlund V; Sundin A; Svenningsson P J Parkinsons Dis; 2012; 2(2):171-80. PubMed ID: 23939442 [TBL] [Abstract][Full Text] [Related]
39. Left hemispheric predominance of nigrostriatal dysfunction in Parkinson's disease. Scherfler C; Seppi K; Mair KJ; Donnemiller E; Virgolini I; Wenning GK; Poewe W Brain; 2012 Nov; 135(Pt 11):3348-54. PubMed ID: 23043142 [TBL] [Abstract][Full Text] [Related]
40. Parkinson disease and sleep: sleep-wake changes in the premotor stage of Parkinson disease; impaired olfaction and other prodromal features. Iranzo A Curr Neurol Neurosci Rep; 2013 Sep; 13(9):373. PubMed ID: 23881622 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]